Tamid Bio, Inc. (Tamid), a Fortress Biotech company, is dedicated to the development of adeno-associated virus (AAV) gene therapies in orphan diseases with unmet medical needs. Tamid has partnered with the University of North Carolina at Chapel Hill (UNC-Chapel Hill) and the UNC Gene Therapy Center in the development of Tamid-001, an AAV gene therapy that targets the ocular manifestations of Mucopolysaccharidosis type I (MPS I). This rare and progressively debilitating disorder is caused by the accumulation of glycosaminoglycans (“GAGs”) in multiple organs. Tamid-001 will aim to provide sustained delivery of the missing enzyme, to remove the GAGs already in the eye and prevent future accumulation. Tamid has also in-licensed two earlier-stage assets from UNC-Chapel Hill which will target dysferlinopathies and corneal transplant rejection. Preclinical and early clinical research programs for these assets will be performed at the UNC Gene Therapy Center. Tamid is headquartered in New York City.